GlassScriptPhysician profile
Julie Samantray
NPI 1285832451
$5,317.07
in general payments reported to CMS, 2019-2025
32 companies · $662 in 2025
The $662 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,210 · 2020: $324 · 2021: $369 · 2022: $278 · 2023: $800 · 2024: $1,673 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,051 · Travel and Lodging: $1,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,050.61 |
| Travel and Lodging | $1,084.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,165.89 | 2022-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Novo Nordisk INC | $366.08 | 2019-2025 | Ozempic, Saxenda, Wegovy |
| Lilly USA, LLC | $355.83 | 2019-2023 | Mounjaro |
| Medtronic Minimed, INC. | $260.62 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $215.38 | 2019-2022 | |
| Radius Health, INC. | $196.51 | 2019-2021 | |
| Amgen INC. | $191.20 | 2019-2025 | Tepezza, Evenity, Prolia |
| Neurocrine Biosciences, INC. | $180.57 | 2024-2025 | |
| Corcept Therapeutics | $179.62 | 2019-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.26 | 2022-2023 | Jardiance |
| Ibsa Pharma INC. | $133.98 | 2021-2023 | Tirosint |
| Becton, Dickinson and Company | $108.15 | 2019-2021 | |
| Pfizer INC. | $90.74 | 2019-2025 | |
| Ultragenyx Pharmaceutical INC. | $86.02 | 2019-2020 | |
| Horizon Therapeutics Plc | $73.79 | 2019-2023 | Tepezza |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $68.52 | 2020-2025 | Isturisa, Signifor Lar |
| Acella Pharmaceuticals, LLC | $66.59 | 2023 | NP Thyroid 60 |
| Insulet Corporation | $58.73 | 2019-2024 | Omnipod |
| Shire North American Group INC | $46.15 | 2019 | |
| Madrigal Pharmaceuticals | $43.52 | 2025 | Rezdiffra |
| Sequel Med Tech, LLC | $37.93 | 2025 | Twiist |
| Ascendis Pharma Endocrinology INC | $28.02 | 2025 | Yorvipath |
| Xeris Pharmaceuticals, INC. | $24.18 | 2024 | Gvoke Hypopen |
| Abbvie INC. | $24.05 | 2024 | |
| Abbott Laboratories | $23.85 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $22.83 | 2019 | |
| Zealand Pharma US, INC. | $21.87 | 2021 | |
| Averitas Pharma INC. | $18.92 | 2023 | Qutenza |
| Dexcom, INC. | $16.14 | 2023 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $14.14 | 2020 | |
| Edwards Lifesciences Corporation | $13.59 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Samantray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.